Sonoma Pharmaceuticals and MicroSafe Group Announce That Microsafe® Disinfectant & Sanitizer Manufactured Using Sonoma’s Microcyn® Technology Successfully Passed Material Compatibility Testing for Both Airbus and Boeing Commercial Transport Aircraft

Download as PDF

WOODSTOCK, Ga.--(BUSINESS WIRE)-- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions and the MicroSafe Group Dubai announce that Microsafe® Disinfectant & Sanitizer manufactured by Sonoma successfully passed both the Boeing Specification Standard BSS7434 and the British Aerospace Airbus specification AIMS09-00-002. The passing of these tests validate the compatibility and safety of the Microsafe® Disinfectant & Sanitizer on the interior and exterior parts and materials of Boeing and Airbus commercial transport aircraft.

“Conforming with the material compatibility standards set forth by Boeing & Airbus, together with our 30 second kill time of bacteria & viruses on hard surfaces, allows us to advance the use of Microsafe® Disinfectant & Sanitizer into the airline industry. Recently, Microsafe® Disinfectant & Sanitizer (brand name “Nanocyn” in Australia) was approved and entered into the Australian Register of Therapeutic Goods (ARTG) for use against SARS-CoV-2 (COVID-19) with a 30 second kill time,” said Mrs. Safa Qadumi, Founder and CEO of the MicroSafe Group Dubai.

“It’s important to note, that the Microsafe® Disinfectant & Sanitizer has been successfully used for nearly 20 years globally to fight the spread of infectious disease and during this time, we have earned numerous global regulatory approvals and amassed reputable scientific evidence not only as a surface disinfectant, but as a skin and wound antiseptic as well,” Mrs. Safa, continued.

“We are excited that these tests show that use of our Microcyn® technology conforms to aircraft manufacturer standards. These test results expand our potential sales channels into the airline industry,” said Amy Trombly, CEO of Sonoma Pharmaceuticals. She continued, “As disinfectant and sanitizer use has increased due to the pandemic that has spread around the world, we are excited to work with our partners, like MicroSafe Group, to make a positive difference by providing safer environments for people during this difficult time. As an international company selling products in 53 countries around the world, we are continuously seeking additional partners to expand our domestic and global reach in distributing our products.”

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 53 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact businessdevelopment@sonomapharma.com.

About MicroSafe Group

The MicroSafe Group is multi-nation company with its head office in Dubai, United Arab Emirates. With several regional offices in the Middle East, as well as MicroSafe Care Australia, MicroSafe Group is able to provide innovative solutions to a wide range of industries and healthcare providers. The MicroSafe Group promotes only those products it believes will truly revolutionize healthcare – products that will enrich the lives of patients and healthcare professionals all over the world. Interested distributors may contact the MicroSafe Group at info@microsafecare.com or contact Mr. Safwan Abdallah, Director of International Business Development at safwan@microsafecare.com. More information can be found at www.microsafe.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “advance,” “develop” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™, Microcyn® and Microdacyn60® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharmaceuticals.com

Source: Sonoma Pharmaceuticals, Inc.

Released July 28, 2020